Skip to main content

Table 1 Key Inclusion Criteria

From: The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study

1. At least 50 years old.

2. Diagnosis of active subfoveal CNV secondary to nAMD confirmed on FA in accordance with PBS eligibility criteria and with evidence of fluid on OCT. Active CNV affecting the fovea was defined on multi-modal imaging as subfoveal CNV (determined on FA) and, in addition, juxtafoveal or extrafoveal CNV where there was a component of the CNV (ie fluid, SHRM) involving the fovea on OCT.

3. At least one treatment-naïve eye.

4. BCVA score of at least 23 letters or more (Snellen visual acuity or equivalent of 20/320).